Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Consensus Rating of “Moderate Buy” from Analysts

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) has been given an average recommendation of “Moderate Buy” by the eight brokerages that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $10.0833.

Several analysts have issued reports on XERS shares. Barclays began coverage on shares of Xeris Biopharma in a research report on Monday, December 8th. They set an “overweight” rating and a $9.00 price target on the stock. Oppenheimer restated an “outperform” rating and set a $18.00 price objective on shares of Xeris Biopharma in a research note on Friday, November 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xeris Biopharma in a report on Wednesday, January 21st. Wall Street Zen cut Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a report on Saturday, November 8th. Finally, HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Xeris Biopharma in a research report on Monday.

Xeris Biopharma Stock Up 2.2%

XERS stock opened at $6.07 on Thursday. The company has a market cap of $1.05 billion, a price-to-earnings ratio of -606.39 and a beta of 0.61. Xeris Biopharma has a twelve month low of $3.65 and a twelve month high of $10.08. The business has a 50 day moving average price of $7.16 and a two-hundred day moving average price of $7.61. The company has a quick ratio of 1.35, a current ratio of 2.19 and a debt-to-equity ratio of 16.10.

Xeris Biopharma (NASDAQ:XERS) last announced its quarterly earnings data on Monday, March 2nd. The company reported $0.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.03 by $0.03. The company had revenue of $85.81 million for the quarter, compared to analysts’ expectations of $86.00 million. Xeris Biopharma had a negative return on equity of 5.33% and a net margin of 0.19%. Analysts anticipate that Xeris Biopharma will post -0.41 EPS for the current fiscal year.

Insider Buying and Selling at Xeris Biopharma

In other Xeris Biopharma news, insider John Patrick Shannon, Jr. sold 24,907 shares of Xeris Biopharma stock in a transaction on Monday, January 5th. The shares were sold at an average price of $7.08, for a total transaction of $176,341.56. Following the completion of the transaction, the insider directly owned 2,705,346 shares of the company’s stock, valued at $19,153,849.68. The trade was a 0.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Kevin Mcculloch sold 15,000 shares of the company’s stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $8.00, for a total transaction of $120,000.00. Following the completion of the transaction, the insider owned 1,685,426 shares in the company, valued at approximately $13,483,408. This represents a 0.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 240,308 shares of company stock worth $1,732,453 in the last three months. 6.47% of the stock is owned by insiders.

Institutional Trading of Xeris Biopharma

Hedge funds and other institutional investors have recently modified their holdings of the stock. UBS Group AG grew its stake in Xeris Biopharma by 682.4% in the 3rd quarter. UBS Group AG now owns 1,782,734 shares of the company’s stock valued at $14,511,000 after buying an additional 1,554,869 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Xeris Biopharma by 13.8% during the fourth quarter. Vanguard Group Inc. now owns 11,186,677 shares of the company’s stock worth $87,815,000 after acquiring an additional 1,358,760 shares during the period. Qube Research & Technologies Ltd grew its position in shares of Xeris Biopharma by 67.5% in the second quarter. Qube Research & Technologies Ltd now owns 3,089,771 shares of the company’s stock valued at $14,429,000 after purchasing an additional 1,245,188 shares during the last quarter. Goldman Sachs Group Inc. grew its position in shares of Xeris Biopharma by 75.4% in the first quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock valued at $15,317,000 after purchasing an additional 1,199,435 shares during the last quarter. Finally, CenterBook Partners LP increased its stake in shares of Xeris Biopharma by 237.7% during the second quarter. CenterBook Partners LP now owns 1,594,229 shares of the company’s stock worth $7,445,000 after purchasing an additional 1,122,154 shares during the period. Institutional investors own 42.75% of the company’s stock.

Key Xeris Biopharma News

Here are the key news stories impacting Xeris Biopharma this week:

• Positive Sentiment: Analyst support — HC Wainwright reiterated a “Buy” rating and a $10 price target while publishing multi-year EPS models that show the company returning to positive earnings by FY2026 and rising thereafter; that bullish stance supports investor optimism. Xeris Biopharma (NASDAQ:XERS) Earns Buy Rating from HC Wainwright
• Positive Sentiment: Earnings beat — Xeris reported Q4 2025 adjusted EPS above consensus (roughly $0.0615 vs. $0.03 expected), indicating improving profitability that investors are rewarding. Xeris Biopharma (XERS) Q4 2025 Earnings Transcript
• Positive Sentiment: Bull thesis coverage — A Seeking Alpha piece argues Xeris is undervalued given its drug portfolio upside, which can attract value-oriented and growth investors. Xeris Biopharma: Undervalued Given The Potential Of Its Drug Portfolio
• Neutral Sentiment: Profitability vs. legal risk — Coverage highlights that Xeris has achieved new profitability metrics but is simultaneously engaged in patent disputes over Recorlev; this balances upside with legal uncertainty, creating a mixed signal for investors. Xeris Biopharma Balances New Profitability With Recorlev Patent Battles
• Negative Sentiment: Insider sale — Director/insider Beth Hecht sold 16,667 shares at about $6.25 on March 2, modestly reducing her stake; insider selling can raise caution among investors even if the position remains large. SEC Form 4 — Beth Hecht
• Negative Sentiment: Analyst estimate cuts — Although HC Wainwright kept a Buy rating, it trimmed several multi-year EPS forecasts (FY2026–FY2029/FY2030 adjustments), which reduces the magnitude of long-term upside implied by prior models. Xeris Biopharma (NASDAQ:XERS) Earns Buy Rating from HC Wainwright

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.